AVITA Medical, Inc. (RCEL)
Health Care · Acute wound care and regenerative medicine devices · NASDAQ
A therapeutic wound care company commercializing RECELL, an autologous cell harvesting device that creates patient-derived skin cell suspension for treating burns and traumatic injuries, now expanding into a multi-product acute wound care platform.
What AVITA Medical, Inc. does
AVITA Medical is a therapeutic acute wound care company that develops and commercializes proprietary skin cell harvesting and wound closure technologies. The company's flagship product RECELL is an autologous cell harvesting device that enables clinicians to create a suspension of a patient's own skin cells (Spray-On Skin) at the point of care for treating burns, traumatic injuries, and surgical wounds. AVITA has expanded into a multi-product platform by distributing complementary wound care products including PermeaDerm (biosynthetic wound matrix) and Cohealyx (collagen-based dermal matrix).
Themes: autologous cell therapy / regenerative medicine, acute wound care / burn treatment, trauma and surgical wound management, dermal matrices / wound bed preparation, point-of-care medical devices
Fundamentals
- Price$10.59 as of 2026-08-26 close
- Market cap$328M as of 2026-08-26
- 1-year return+132.2% 2025-08-26 close $4.56 → 2026-08-26 close $10.59
- P/En/a negative earnings
- Net margin-62.7% as of 2026-08-27
- Gross margin+82.1% as of 2026-08-27
- ROE-337.9% as of 2026-08-27
- Debt / equity9.39 as of 2026-08-27
- Revenue growth (YoY)+1.0% as of 2026-08-27
- Revenue CAGR (3y)+27.7% SEC XBRL
- Beta2.01 as of 2026-08-27
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How RCEL compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-27
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-27
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-27
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-27
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How AVITA Medical, Inc. looks technically
AVITA Medical, Inc. (RCEL) is trading 134.6% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 85 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 48, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 81, in overbought territory (above 70). It just made a new 20-day high, pushing above its recent trading range. It is 1.7% below its 52-week high (its highest price of the past year). Trading volume is unusually light — only about 43% of its 30-day average.
Trend
9
| Distance from the 200-day | it is trading 134.6% above its 200-day average, the long-term trend line — a longer-term uptrend | +134.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $5.76 | $5.76 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $4.51 | $4.51 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 26 calendar days ago — the swings before that are what the structure reading is measured on | 26 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 4.24. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 85 trading days ago — a "golden cross", a bullish long-term signal | 85 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 134.6% above | +134.6% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 48, with buyers in control | 48.4 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 81, in overbought territory (above 70) | 81.1 |
|---|---|---|
| Position in its 14-day range | it is trading right at the top of its 14-day range ($5.99 to $10.77) — its "stochastic" reading is 96 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 96.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 14 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $10.77 | $10.77 |
|---|---|---|
| From the 52-week high | it is 1.7% below its 52-week high (its highest price of the past year) | -1.7% |
| Above the 52-week low | it is 228.9% above its 52-week low (its lowest price of the past year) | +228.9% |
| Below the 52-week high | it is 1.7% below its highest point of the past year | 1.7% |
| Since a 20-day breakout | it just made a new 20-day high, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $55.35 (set on 2020-02-19) | $55.35 |
| Given back of the 52-week move | over the past year its closes ranged ($3.27 to $10.59), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $5.83 to $6.07. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 80.9% below its all-time high | -80.9% |
| Nearest price level | it is trading 4.0% below a resistance level at $11.01 — a price it turned at three times since 2024-09-20, most recently on 2024-10-16. Since 2024-08-26 it has 12 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +4.0% |
| All-time low | its lowest closing price on record is $3.22 (set on 2026-01-07) | $3.22 |
| Above the all-time low | it is 228.9% above its all-time low | +228.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 94% of the past ~6 months) | 94th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.6959 between its high and its low — about 6.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.6959 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.15 and $12.26 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.15 – $7.71 – $12.26 |
| Typical daily range (% of price) | its price moves about 6.6% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.6% |
| Stretch from the 200-day average | it is trading 8.7 daily ranges above its 200-day average price (134.6% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 8.7 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 43% of its 30-day average | 0.43× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 23.0% since the prior reading | +23.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 7 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 7 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-26 0.3% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.3% |
|---|---|---|
| Open gap | it gapped 26.5% above the previous close 13 sessions ago and has not traded back through the level it left behind at 4.75 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +26.5% |
| Gap filled | a 2.1% gap up opened on 2026-08-21 has been "filled" 3 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 3 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +6.86% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 126.0 percentage points (the stock gained 129.7% while the market gained 3.7%) | +126.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 147.1 percentage points (the stock gained 149.2% while the market gained 2.1%) | +147.1% |
| vs market, 6 months | over the past 6 months this stock beat the market by 96.1 percentage points (the stock gained 107.2% while the market gained 11.1%) | +96.1% |
| vs market, 12 months | over the past 12 months this stock beat the market by 113.5 percentage points (the stock gained 132.2% while the market gained 18.7%) | +113.5% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 122% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-21 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 0.2% of the share price, which is taken to mean a barrier that gives way easily. | +122.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 92% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $5.52 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +91.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 27% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $8.34 — a volume-weighted average of daily closes over 15 sessions, not a true tick-by-tick VWAP. | +27.0% |
Price levels it has turned at before
RCEL last closed at $10.59 on 2026-08-26. Since 2024-08-26 it has turned at 12 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $11.01 | Resistance | 4.0% above the last close | turned there three times · 2024-09-20 to 2024-10-16 |
| $11.28 | Resistance | 6.5% above the last close | turned there twice · 2024-12-19 to 2025-02-14 |
| $9.78 | Support | 7.7% below the last close | turned there four times · 2024-10-10 to 2025-05-08 |
| $8.36 | Support | 21.1% below the last close | turned there twice · 2025-01-23 to 2025-02-12 |
| $13.89 | Resistance | 31.2% above the last close | turned there three times · 2024-11-20 to 2024-12-27 |
| $6.34 | Support | 40.1% below the last close | turned there twice · 2025-06-06 to 2025-07-24 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $4.24.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $6.16 and $7.35 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $4.24.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-26.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Overbought (14-day RSI above 70) · Near the 52-week high · Broke out to a new 20-day high · in a strong, established uptrend (ADX) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-26. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 3 analysts
- Mean price target$11.13 range $8.16 – $14.11; median $11.12
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for RCEL
- Consensus EPS estimate-A$0.2928 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Regulatory and reimbursement risks: dependence on FDA approvals and third-party payor coverage determinations for RECELL and complementary products; failure to obtain or maintain favorable coverage could materially impact revenue growth","Market adoption and competition: ability to expand market penetration in burn centers and trauma/surgical settings; increasing competition and need to scale commercial infrastructure to meet demand","Profitability and liquidity: significant operating losses (-62.67% net margin), flat revenue growth (0.96% YoY), and need to achieve positive cash flow and long-term profitability; covenant compliance risks on debt obligations"]
What changed in the latest 10-Q
AI-assisted comparison of RCEL's 10-Q filed 2026-05-14 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to 'Note Regarding Forward-Looking Statements' on page 3 moved into opening paragraph (2026-05-14 filing)
- Description of RECELL as creating 'Spray-On Skin' (without 'Cells' designation) (2026-05-14 filing)
- Addition of RECELL GO mini trademark symbol (®) designation (2026-05-14 filing)
- Execution of focused commercial strategy centered on approximately 200 U.S. burn and trauma centers (2026-05-14 filing)
- Statement that 'these institutions are core to our commercialization efforts' with explanation of high concentration of complex inpatient cases (2026-05-14 filing)
- Specific reimbursement impact disclosure: CMS designated pricing responsibility to seven regional MACs in 2025, with delay in establishing rates that temporarily slowed clinician use (2026-05-14 filing)
- Update that as of March 2026, all seven MACs have published rates, restoring reimbursement clarity (2026-05-14 filing)
- Disclosure of credit facility with Perceptive Advisors LLC on January 13, 2026 for up to $60 million (2026-05-14 filing)
- Details of $50 million drawn at closing with approximately $6.0 million net proceeds after debt repayment (2026-05-14 filing)
- Option to access additional $10.0 million through first quarter of 2027 subject to revenue milestone (2026-05-14 filing)
- Specific TTM revenue covenants: $68.5 million for Q1 2026, $69.0 million for Q2 2026, $73.0 million for full year 2026 (2026-05-14 filing)
- Compliance confirmation as of March 31, 2026 with covenants (2026-05-14 filing)
- Addition of Asia to list of geopolitical regions not having company operations (2026-05-14 filing)
- Removed:
- Forward-looking statements cautionary language from opening paragraph (present in 2025-11-06 filing)
- Statement that results 'may differ materially from the results discussed, projected, anticipated, or indicated' (2025-11-06 filing)
- Reference to Part II, Item 1A, Risk Factors (2025-11-06 filing)
- Caution about not placing undue reliance on forward-looking statements (2025-11-06 filing)
- Disclaimer regarding obligation to update forward-looking statements except as required by law and SEC/ASIC rules (2025-11-06 filing)
- Description of RECELL as 'patented and proprietary RECELL System' (2025-11-06 filing)
- Language that RECELL creates 'autologous skin cell suspension, Spray-On Skin Cells' (2025-11-06 filing)
- Language that Regenity 'will manufacture and supply' and company 'will hold' exclusive rights (future tense) (2025-11-06 filing)
- Language regarding PermeaDerm appearing before Cohealyx in product listing (2025-11-06 filing)
- Strategic objective bullets referencing specific actions: 'Increase market penetration...including reduction in length of stay' (2025-11-06 filing)
- Strategic objective 'Expand adoption of RECELL GO mini in trauma and burn centers' (separate bullet) (2025-11-06 filing)
- Strategic objective 'Continue enrollment of the post-market study of Cohealyx in 2025' (2025-11-06 filing)
- Strategic objective 'Continue enrollment of the post-market study of PermeaDerm in 2025' (2025-11-06 filing)
- Strategic objective 'After obtaining CE mark for RECELL GO, commercialization in the European Union, the U.K., and Australia' (2025-11-06 filing)
- Strategic objective 'Drive commercial revenue growth, generate positive cash flow, and achieve operating profitability' (2025-11-06 filing)
- Reference to 'Seek additional business development opportunities' (2025-11-06 filing)
- Statement that issue with reimbursement 'contributed to a decline in demand for the RECELL System during the first half of the year' (2025-11-06 filing)
- Statement that 'recent advocacy efforts are progressing towards a resolution which is expected to drive revenue recovery' (2025-11-06 filing)
- Language 'other related global economic conditions and geopolitical conditions' (2025-11-06 filing)
- Language 'and/or an escalation of the conflicts beyond their current scope' (2025-11-06 filing)
- Text appears truncated in 2025-11-06 filing ending mid-sentence on 'supply constraint' (2025-11-06 filing)
- Reworded:
- Strategic objectives language changed from 'Increase' to 'Increasing' (action-oriented restructuring) (2026-05-14 filing)
- Strategic objective changed from 'Expand adoption of the RECELL portfolio for the treatment of traumatic and surgical wounds' to 'Expanding adoption of RECELL for the treatment of traumatic and surgical wounds' (2026-05-14 filing)
- Strategic objective regarding Cohealyx changed from 'Expand adoption of Cohealyx' to 'Commercializing and expanding adoption of Cohealyx as a dermal matrix that supports wound bed preparation and meaningfully reduces mean time to skin grafting' (2026-05-14 filing)
- Strategic objective regarding RECELL GO mini changed from separate bullet to integrated with Cohealyx approach (2026-05-14 filing)
- Strategic objectives regarding post-market studies changed from specific 2025 enrollment targets to general 'Advancing post-market clinical studies for Cohealyx and PermeaDerm to generate additional clinical and health economic evidence supporting adoption' (2026-05-14 filing)
- Strategic objective regarding international expansion changed from 'After obtaining CE mark for RECELL GO, commercialization in the European Union, the U.K., and Australia' to 'Expanding internationally through distributor-led commercialization upon receipt of regulatory approvals' (2026-05-14 filing)
- Strategic objective regarding profitability changed from 'Drive commercial revenue growth, generate positive cash flow, and achieve operating profitability' to 'Driving commercial revenue growth, improving operating leverage, generating positive cash flow, and achieving long-term operating profitability' (2026-05-14 filing)
- Strategic objective regarding business development changed from 'Seek additional business development opportunities complementary to our target markets' to 'Pursuing additional business development opportunities complementary to our target wound care markets' (2026-05-14 filing)
- Reimbursement discussion changed from general statement about advocacy efforts to specific disclosure of CMS regional MAC structure and resolution status (2026-05-14 filing)
- Notes:
- Older filing (2025-11-06) text appears truncated at end of geopolitical conditions section, potentially omitting content for comparison
- Recent Developments section in 2026-05-14 filing also appears truncated mid-sentence ('For additional information, see Liquidity and Capit'), suggesting incomplete extraction
Risk Factors
- Added:
- Added reference to 'Annual Report on Form 10-K for the year-ended December 31, 2025 filed with the SEC on February 12, 2026' in forward-looking statements section (filed 2026-05-14)
- Added statement 'There have been no material changes to the risk factors described in Part I, Item 1A, "Risk Factors," included in the Company's Annual Report on Form 10-K for the year-ended December 31, 2025' (filed 2026-05-14)
- Added lodged with 'Australian Securities Exchange ("ASX") on February 13, 2026' reference (filed 2026-05-14)
- Removed:
- Removed 'or failure to obtain, maintain and enforce our intellectual property rights' language changed to 'ability to obtain, maintain and enforce our intellectual property rights' (filed 2025-11-06 had 'failure to obtain' and 'failure to obtain and/or maintain regulatory approvals')
- Removed 'if third parties fail to uphold their contractual duties or meet expected deadlines' replaced with 'performance by third parties of their contractual duties or expected deadlines' (filed 2026-05-14)
- Removed 'failure to obtain and/or maintain regulatory approvals and comply with applicable regulations' and replaced with 'ability to obtain and/or maintain regulatory approvals and comply with applicable regulations' (filed 2026-05-14)
- Removed reference to 'the impact of a cybersecurity breach, terrorist attack or other geopolitical instability, pandemic or epidemic, or natural disaster' (filed 2025-11-06, not in filed 2026-05-14)
- Removed reference to risk factors in 'this Quarterly Report on Form 10-Q titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations"' and replaced with reference to 'Part I, Item 1A, "Risk Factors," in the Company's Annual Report on Form 10-K' (filed 2026-05-14)
- Reworded:
- Changed 'future revenue; or future growth' to 'future revenue; or future growth' with restructured punctuation and syntax (filed 2026-05-14)
- Changed reference from 'sections in this Quarterly Report' to reference to '10-K for the year-ended December 31, 2025' (filed 2026-05-14)
- Consolidated 'tax and interest rates; inflationary pressures on the U.S. and global economies, respectively; changes in the legal or regulatory environments' into 'taxes, interest rates, and inflationary pressures, and future working capital costs; changes in the legal or regulatory environments' (filed 2026-05-14)
- Reordered 'future working capital costs' to appear earlier in list, removed 'rationalization' and 'investment (including rates)' specificity from 'working capital, costs, productivity, business process, rationalization, investment (including rates), consulting, operational, financial, and capital projects' (filed 2026-05-14)
- Changed forward-looking indicator term from 'anticipate' to removed 'anticipate' (filed 2026-05-14 vs filed 2025-11-06)
- Notes:
- The newer filing contains only header and forward-looking statement content, while older filing also contains financial statements; comparison limited to forward-looking statements section
- The texts appear to describe different time periods (March 31, 2026 vs September 30, 2025) which is expected for different quarterly filings
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
9 open-market purchases and 0 open-market sales by insiders in the last 90 days.
- Last 90 days9 buys ($188586) · 0 sells — 1 buying insider
- Last 180 days11 buys ($205586) · 0 sells — 2 buying insiders
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-09. As of 2026-08-27.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about RCEL's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding RCEL as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 1,616,408
- Reported value $5,980,710
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
RCEL had 2,607,471 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
RCEL had 8.43% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 11.1 days to cover at the same settlement.
- Reported short interest (shares) 2,607,471
- Short interest (% of shares outstanding) 8.43%
- Prior settlement (shares) 2,617,186
- Reported change -0.37%
- Days to cover (reported) 11.1
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Integra LifeSciences (IART)
- Organogenesis (ORGO)
- MiMedx (MDXG)
- Smith & Nephew
- 3M (MMM)
- Stryker (SYK)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare RCEL vs…
RCEL ranks in…
Frequently asked questions
What does AVITA Medical, Inc. (RCEL) do?
AVITA Medical is a therapeutic acute wound care company that develops and commercializes proprietary skin cell harvesting and wound closure technologies. The company's flagship product RECELL is an autologous cell harvesting device that enables clinicians to create a suspension of a patient's own skin cells (Spray-On Skin) at the point of care for treating burns, traumatic injuries, and surgical wounds.
What sector is AVITA Medical, Inc. (RCEL) in?
AVITA Medical, Inc. (RCEL) is classified in the Health Care sector. Its industry is Acute wound care and regenerative medicine devices. It trades on NASDAQ.
Who are AVITA Medical, Inc.'s (RCEL) competitors?
Notable peers of AVITA Medical, Inc. (RCEL) include Integra LifeSciences, Organogenesis, MiMedx, Smith & Nephew and 3M. This peer set is informational only — not financial advice.
Is AVITA Medical, Inc. (RCEL) overbought or oversold right now?
AVITA Medical, Inc. (RCEL) is currently in overbought territory (its 14-day RSI is 81, above 70) (as of 2026-08-26). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on RCEL come from?
Fundamentals and prices come from market data, as of 2026-08-27; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-27. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-26.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.